Caution: bevacizumab-based regimens with untreated varices
Immunotherapy plus bevacizumab is standard in liver cancer, but the anti-VEGF part can cause fatal bleeding from swollen veins in the oesophagus unless they are checked first.
IMbrave150 required endoscopy within 6 months and treatment of varices; upper-GI bleeding was 7% with atezolizumab-bevacizumab. STRIDE (HIMALAYA) or nivolumab-ipilimumab are alternatives for patients at high bleeding risk.
Pages like this
not linked directly; found by shared links- PersonHo Yeong Lim
Shares IMbrave150, Atezolizumab, Hepatocellular carcinoma.
- TrialIMbrave050
Shares Atezolizumab, Hepatocellular carcinoma.
- ProductTremelimumab
Shares HIMALAYA, Durvalumab, Hepatocellular carcinoma.
- IdeaImmunotherapy downstaging to transplant with a safe washout
Shares Atezolizumab, Hepatocellular carcinoma.
- TrialEMERALD-1
Shares Durvalumab, Hepatocellular carcinoma.
- InstitutionIRCCS Humanitas Research Hospital
Shares Durvalumab, Atezolizumab, Hepatocellular carcinoma.
- TermLimited-stage vs extensive-stage (small-cell lung cancer)
Shares Durvalumab, Atezolizumab.
- TechnologyHCC surveillance in cirrhosis (ultrasound + AFP)
Shares Hepatitis B and C as cancer causes, Hepatocellular carcinoma.